This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

CSCO, Xiamen, China, 18 - 22 September 2019

Afatinib in EGFR TKI-naïve patients with EGFR-mutation positive NSCLC: interim analysis from a Phase IIIb, open-label study

Filippo De Marinis, Konstantin K Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, Guzel Z Mukhametshina,  Michael Schumacher,  Silvia Novello, Rafal Dziadziuszko, Wenbo Tang, Laura Clementi, Agnieszka Cseh, Dariusz Kowalski,

1200.55_csco_oral_presentationimage.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY.

image